"These differences were largely driven by the high rate of adverse events leading to study discontinuation in the OIT-treated participants, despite receiving omalizumab treatment at the initiation of therapy."
Moxifloxacin carries the highest anaphylaxis risk among fluoroquinolones, while the entire drug class shows a lower risk than amoxicillin, Penn State researchers reported.